The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia

被引:1
作者
Jovanovic-Cupic, Snezana [1 ]
Glisic, Sanja [2 ]
Stanojevic, Maja [3 ]
Nozic, Darko [4 ]
Petrovic, Nina [1 ]
Mandusic, Vesna [1 ]
Krajnovic, Milena [1 ]
机构
[1] Univ Belgrade, Inst Nucl Sci, Lab Radiobiol & Mol Genet, POB 522, Belgrade 11000, Serbia
[2] Univ Belgrade, Inst Nucl Sci, Ctr Multidisciplinary Res, POB 522, Belgrade 11000, Serbia
[3] Univ Belgrade, Fac Med, Inst Microbiol & Immunol, Belgrade 11000, Serbia
[4] Mil Med Acad, Clin Infect & Trop Dis, Belgrade 11000, Serbia
关键词
SUSTAINED VIROLOGICAL RESPONSE; ALPHA PLUS RIBAVIRIN; FIBROSIS PROGRESSION; COMBINATION THERAPY; ION-CHANNEL; VIRUS P7; HCV P7; PEGINTERFERON; PROTEIN; RNA;
D O I
10.1007/s00705-016-2777-z
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p < 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p < 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p < 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
引用
收藏
页码:1189 / 1198
页数:10
相关论文
共 50 条
  • [1] RESPONSE FACTORS TO PEGYLATED INTERFERON-ALFA/RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C PATIENTS GENOTYPE 1B
    Jovanovic-Cupic, Snezana
    Glisic, S.
    Stanojevic, M.
    Vasiljevic, N.
    Bojic-Milinovic, T.
    Bozovic, A.
    Dimitrijevic, B.
    ARCHIVES OF BIOLOGICAL SCIENCES, 2014, 66 (01) : 193 - 201
  • [2] Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response
    Ikeda, Hiroki
    Suzuki, Michihiro
    Okuse, Chiaki
    Yamada, Norie
    Okamoto, Masaru
    Kobayashi, Minoru
    Nagase, Yoshihiko
    Takahashi, Hideaki
    Matsunaga, Koutarou
    Matsumoto, Nobuyuki
    Itoh, Fumio
    Yotsuyanagi, Hiroshi
    Koitabashi, Yu
    Yasuda, Kiyomi
    Iino, Shiro
    HEPATOLOGY RESEARCH, 2009, 39 (08) : 753 - 759
  • [3] Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
    Yen, Yi-Hao
    Wang, Jyh-Chwan
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Wang, Jing-Houng
    Hu, Tsung-Hui
    Kee, Kwong-Ming
    Hsiao, Chang-Chun
    Lee, Chuan-Mo
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (07) : 652 - 658
  • [4] Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load
    Kim, Soo Ryang
    El-Shamy, Ahmed
    Imoto, Susumu
    Kim, Ke Ih
    Ide, Yoshi-hiro
    Deng, Lin
    Shoji, Ikuo
    Tanaka, Yasuhito
    Hasegawa, Yutaka
    Ota, Mitsuhiro
    Hotta, Hak
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (10) : 1143 - 1151
  • [5] Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin
    Yee, Brittany E.
    Nguyen, Nghia H.
    Zhang, Bing
    Vutien, Philip
    Wong, Carrie R.
    Lutchman, Glen A.
    Nguyen, Mindie H.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (11) : 1189 - 1201
  • [6] Prediction of a Null Response to Pegylated Interferon α-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
    Wada, Yuki
    Tamai, Hideyuki
    Kawashima, Akira
    Shingaki, Naoki
    Mori, Yoshiyuki
    Kawaguchi, Masanori
    Moribata, Kosaku
    Deguchi, Hisanobu
    Ueda, Kazuki
    Inoue, Izumi
    Maekita, Takao
    Iguchi, Mikitaka
    Kato, Jun
    Ichinose, Masao
    GUT AND LIVER, 2014, 8 (04) : 421 - 427
  • [7] Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Kawamura, Yusuke
    Yatsuji, Hiromi
    Hosaka, Tetsuya
    Akuta, Norio
    Kobayashi, Masahiro
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Miyakawa, Yuzo
    Kumada, Hiromitsu
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (06) : 1317 - 1324
  • [8] Individualized Extension of Pegylated Interferon Plus Ribavirin Therapy for Recurrent Hepatitis C Genotype 1b After Living-Donor Liver Transplantation
    Ueda, Yoshihide
    Takada, Yasutsugu
    Marusawa, Hiroyuki
    Egawa, Hiroto
    Uemoto, Shinji
    Chiba, Tsutomu
    TRANSPLANTATION, 2010, 90 (06) : 661 - 665
  • [9] Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b
    Glisic, Sanja
    Veljkovic, Nevena
    Cupic, Snezana Jovanovic
    Vasiljevic, Nada
    Prljic, Jelena
    Gemovic, Branislava
    Perovic, Vladimir
    Veljkovic, Veljko
    PROTEIN JOURNAL, 2012, 31 (02) : 129 - 136
  • [10] Hepatitis C Virus Genotype 1: How Genetic Variability of the Core Protein Affects the Response to Pegylated-Interferon and Ribavirin Therapy
    Alhamlan, F. S.
    Al-Ahdal, M. N.
    Khalaf, N. Z.
    Abdo, A. A.
    Sanai, F. M.
    Al-Ashgar, H. I.
    ElHefnawi, M.
    Zaid, A.
    Al-Qahtani, A. A.
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (02) : 224 - 234